The Summit Therapeutics study on PD1-VEGF antibody ivonescimab showcased promising results in delaying lung cancer progression among patients. This achievement aligns with prior findings and marks a significant milestone in Phase 3 clinical trials, highlighting advancements in cancer treatment. As the ASCO conference unfolds, these developments underscore the ongoing efforts to combat cancer globally, offering hope for improved patient outcomes and therapeutic strategies.
Read more from statnews.com
